CLPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
ClearPoint Neuro's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $0.81.
The industry rank for ClearPoint Neuro's Net-Net Working Capital or its related term are showing as below:
The historical data trend for ClearPoint Neuro's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net-Net Working Capital | Get a 7-Day Free Trial | 0.05 | -0.24 | 1.76 | 1.04 | 0.33 |
ClearPoint Neuro Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Net-Net Working Capital | Get a 7-Day Free Trial | 0.85 | 0.53 | 0.44 | 0.33 | 0.81 |
For the Medical Devices subindustry, ClearPoint Neuro's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where ClearPoint Neuro's Price-to-Net-Net-Working-Capital falls into.
ClearPoint Neuro's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as
Net-Net Working Capital | (A: Dec. 2023 ) | ||||||
= | (Cash, Cash Equivalents, Marketable Securities | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (23.14 | + | 0.75 * 3.211 | + | 0.5 * 7.911 | - | 21.488 |
- | 0 | - | 0) | / | 24.6527 | ||
= | 0.33 |
ClearPoint Neuro's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as
Net-Net Working Capital | (Q: Mar. 2024 ) | ||||||
= | (Cash, Cash Equivalents, Marketable Securities | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (35.353 | + | 0.75 * 2.511 | + | 0.5 * 7.96 | - | 19.053 |
- | 0 | - | 0) | / | 27.4163 | ||
= | 0.81 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
ClearPoint Neuro (NAS:CLPT) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Thank you for viewing the detailed overview of ClearPoint Neuro's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
Lynnette C Fallon | director | 108 CHERRY HILL DRIVE, BEVERLY MA 01915 |
Linda M. Liau | director | 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075 |
Mazin Sabra | officer: Chief Operating Officer | 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075 |
Joseph Michael Burnett | director, officer: CEO and President | C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618 |
L. Jeremy Stigall | officer: GM, Biologics & Drug Delivery | 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075 |
Danilo D'alessandro | officer: Vice President, Finance | 5 MUSICK, IRVINE CA 92618 |
Harold A Hurwitz | officer: Chief Financial Officer | |
R John Fletcher | director | C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070 |
Girin Pascal E R | director | C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618 |
B Kristine Johnson | director | 366 FERNDALE RD S, WAYZATA MN 55391 |
Timothy T. Richards | director | ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103 |
Matthew B. Klein | director | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Marcio Souza | director | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Voyager Therapeutics, Inc. | 10 percent owner | 75 HAYDEN AVENUE, LEXINGTON MA 02421 |
Wendelin C Maners | officer: Vice President, Marketing | ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103 |
From GuruFocus
By PurpleRose PurpleRose • 07-26-2022
By sperokesalga sperokesalga • 04-28-2023
By GuruFocusNews GuruFocusNews • 07-02-2022
By sperokesalga sperokesalga • 04-20-2023
By GuruFocusNews GuruFocusNews • 06-29-2022
By Marketwired • 08-08-2023
By sperokesalga sperokesalga • 04-18-2023
By PurpleRose PurpleRose • 07-21-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By GuruFocusNews GuruFocusNews • 06-22-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.